Irvine-based Inbrace, a maker of “invisible braces” which said it had record sales and raised $45 million in Series C funding, has named Kevin Cousins chief financial officer.
“It’s important to put focused expertise in the right leadership positions,” said Dr. John Pham, chief executive and co-founder of Inbrace. “Kevin brings the ideal combination of business acumen, unquestionable integrity and leadership skills needed to leverage our financial position as a well-funded startup.”
Former CFO Kenny Chang has moved into a new role as senior vice president of enterprise development.
The company offers consumers a discrete treatment to hide braces when straightening teeth. It uses a material called nitinol, which has been used for decades in cardiac implants.
Inbrace last October raised $45 million, led by a group of longtime medical investment firms: Vivo Capital, Novo Holdings and venBio Partners.
Cousins has more than 30 years in senior executive leadership positions, including initial public offerings and mergers and acquisitions totaling in excess of $1 billion. These companies include Biopsys Medical, which was acquired by Johnson & Johnson, Sequent Medical, acquired by Microvention/Terumo, Focal Therapeutics, bought by Hologic, and Senorx and Neomend, which both were acquired by CR Bard. He also counted a short stint at Laguna Hills dental products maker Sonendo, which a month ago raised $85 million in financing and was profiled in the Jan. 27 print edition of the Business Journal.
Cousins began his career in public accounting with KPMG predecessor Peat Marwick. He received his master’s in taxation from Golden State University and his bachelor’s in business administration with an emphasis in accounting from California State University-Fullerton.
